Skip to main content
Rohit Aggarwal, MD, Rheumatology, Pittsburgh, PA

Rohit Aggarwal MD


Assistant Professor, Medicine, University of Pittsburgh School of Medicine

Join to View Full Profile
  • 3601 5th AveSuite 3B Falk Medical BuildingPittsburgh, PA 15213

  • Phone+1 412-647-6700

Dr. Aggarwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterFellowship, Rheumatology, 2007 - 2009
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
  • Delhi University College of Medical Sciences
    Delhi University College of Medical SciencesClass of 2003

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2023 - Present
  • ME State Medical License
    ME State Medical License Current
  • PA State Medical License
    PA State Medical License 2004 - 2026
  • IL State Medical License
    IL State Medical License 2007 - 2011
  • Rheumatology
    American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
  • Fellow American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Author Correction: Treatment in Myositis  
    Chester V Oddis, Rohit Aggarwal, Nature

Lectures

  • Autoantibodies Predict Treatment Response to Rituximab in Myositis 
    76th Annual Scienific Meeting, Washington, DC, USA
  • Autoantibodies Predict Treatment Response to Rituximab in Myositis 
    American College of Rheumatology, 76th Annual Scienific Meeting, Washington, DC, USA

Other

Press Mentions

  • CT Results in Myositis Inform Cancer Screening Strategies
    CT Results in Myositis Inform Cancer Screening StrategiesMarch 24th, 2023
  • FDA Approves IV Immunoglobulin to Treat Adults with Dermatomyositis
    FDA Approves IV Immunoglobulin to Treat Adults with DermatomyositisAugust 17th, 2021
  • FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
    FDA Approves Octapharma’s Octagam® 10% for Adult DermatomyositisJuly 20th, 2021
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: